Puzo Michael J Makes New $1.23 Million Investment in Roche Holding AG $RHHBY

Key Points

• Puzo Michael J purchased 23,940 Roche Holding AG shares worth approximately $1.23 million during the second quarter.
• Analyst sentiment is mixed: Morgan Stanley upgraded Roche to “overweight” with a $63 target, while HSBC and Zacks Research downgraded the stock. The consensus rating remains “Hold,” with an average price target of $60.
• Roche shares opened at $58.40, up 5.2%, and are trading near their 12-month high of $60.85; the company operates across pharmaceutical and diagnostics businesses.

Puzo Michael J purchased a new position in shares of Roche Holding AG (OTCMKTS:RHHBY - Free Report) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 23,940 shares of the company's stock, valued at approximately $1,229,000.

Other large investors have also made changes to their positions in the company. McIlrath & Eck LLC acquired a new stake in shares of Roche in the first quarter valued at about $39,000. Oakworth Capital Inc. grew its position in Roche by 20.8% during the fourth quarter. Oakworth Capital Inc. now owns 1,658 shares of the company's stock worth $86,000 after buying an additional 285 shares during the period. Atlas Capital Advisors Inc. acquired a new position in Roche during the fourth quarter worth about $192,000. Pinnacle Wealth Management Advisory Group LLC purchased a new position in Roche in the first quarter valued at about $208,000. Finally, Enterprise Financial Services Corp lifted its position in shares of Roche by 6.6% during the 1st quarter. Enterprise Financial Services Corp now owns 5,576 shares of the company's stock valued at $277,000 after acquiring an additional 345 shares during the period.

Analysts Set New Price Targets

Several equities research analysts have recently commented on RHHBY shares. Morgan Stanley raised Roche from an "equal weight" rating to an "overweight" rating and set a $63.00 price target on the stock in a research note on Friday, August 7th. HSBC downgraded Roche from a "buy" rating to a "hold" rating in a research note on Monday, July 6th. Finally, Zacks Research cut Roche from a "hold" rating to a "strong sell" rating in a report on Tuesday, July 14th. Five research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Hold" and an average target price of $60.00.

Roche Stock Up 5.2%

Roche stock opened at $58.40 on Thursday. Roche Holding AG has a 12-month low of $39.50 and a 12-month high of $60.85. The company has a quick ratio of 1.12, a current ratio of 1.38 and a debt-to-equity ratio of 0.72. The firm's 50-day moving average is $53.06 and its two-hundred day moving average is $52.92.

About Roche

Roche Holding AG is a Swiss multinational healthcare company headquartered in Basel, founded in 1896 by Fritz Hoffmann‑La Roche. The company operates primarily through two complementary divisions — Pharmaceuticals and Diagnostics — and is known for integrating drug development with diagnostic capabilities to advance personalized healthcare. In the United States and other international markets, shares trade as American Depositary Receipts under the ticker RHHBY OTCMKTS: RHHBY.

In pharmaceuticals, Roche focuses on developing and commercializing prescription medicines across therapeutic areas including oncology, immunology, infectious diseases and neuroscience, with a notable emphasis on targeted biologics and personalized therapies.

Want to see what other hedge funds are holding RHHBY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Roche Holding AG (OTCMKTS:RHHBY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source